Arcus Biosciences, Inc. last reported quarterly results on Oct 21, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $3.0 million (-50.0% year over year) and diluted EPS of -$1.00. It usually reports 21–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 24, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 25, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 21–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 21, 2026
21 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
3
-50.0%
|
-128
+5.2%
|
-1.00
+21.3%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
33
+312.5%
|
-91
|
-0.72
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
7
-12.5%
|
-128
-14.3%
|
-1.02
+10.5%
|
|
Feb 25, 2026
56 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
11
-52.2%
|
-106
-12.8%
|
-0.90
+12.7%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
6
-14.3%
|
-135
-46.7%
|
-1.27
-27.0%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
8
-27.3%
|
0
+100.0%
|
0.00
+100.0%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
8
-20.0%
|
-112
-2700.0%
|
-1.14
-2180.0%
|
|
Feb 18, 2025
49 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
23
+146.9%
|
-94
-16.0%
|
-1.03
+4.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RCUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1724521
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.